{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:26:50Z","timestamp":1783344410950,"version":"3.54.6"},"reference-count":23,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radiation is standard therapy for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin-induced lung injury and radiation toxicity. Brentuximab vedotin is highly active in relapsed HL and was recently approved with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated stage III\/IV HL. We evaluated brentuximab-AVD for nonbulky stage I\/II HL in a multicenter phase 2 study. Patients received a lead-in cycle of brentuximab vedotin monotherapy on days 1 and 15, followed by an exploratory positron emission tomography\/computed tomography scan. Patients then received brentuximab-AVD for 4 to 6 cycles based on interim positron emission tomography\/computed tomography scanning after cycle 2. Thirty-four patients were enrolled with a median age of 36 years (range, 20-75 years). Risk was early favorable in 62% and unfavorable in 38%. The best complete response rate was 100%. At a median follow-up of 38 months, the progression-free survival and overall survival were 94% and 97%, respectively. The most common adverse events were peripheral sensory neuropathy (79%), neutropenia (76%), fatigue (74%), and nausea (71%). The most common grade 3\/4 toxicities were neutropenia (62%), febrile neutropenia (35%), and peripheral sensory neuropathy (24%). One elderly patient died of neutropenic sepsis in the first brentuximab-AVD cycle. Brentuximab dose reductions were required in 38% of patients, most for peripheral neuropathy. In conclusion, brentuximab-AVD without bleomycin or radiation produced a high complete response rate, with most patients requiring only 4 total cycles of therapy. Because toxicity was higher than would be expected from AVD alone, this method may not be appropriate for early-stage patients with a highly favorable prognosis. This trial was registered at www.clinicaltrials.gov as #NCT01534078.<\/jats:p>","DOI":"10.1182\/blood.2019001272","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T21:35:16Z","timestamp":1560288916000},"page":"606-613","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Arnason","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-1909","authenticated-orcid":false,"given":"Jeffrey A.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-8082","authenticated-orcid":false,"given":"Robin","family":"Joyce","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Avigan","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Takvorian","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.","family":"Bello","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2020021109244838600_B1","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2020021109244838600_B2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"21","key":"2020021109244838600_B3","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin\u2019s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021109244838600_B4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021109244838600_B5","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2020021109244838600_B6","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2020021109244838600_B7","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2020021109244838600_B8","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/annonc\/mdh465","article-title":"Treatment of stage I and II Hodgkin\u2019s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study","volume":"15","author":"Rueda Dom\u00ednguez","year":"2004","journal-title":"Ann Oncol"},{"issue":"9","key":"2020021109244838600_B9","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2009.25.3260","article-title":"Treatment of favorable, limited-stage Hodgkin\u2019s lymphoma with chemotherapy without consolidation by radiation therapy","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020021109244838600_B10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/annonc\/mdq549","article-title":"End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin\u2019s lymphoma","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"17","key":"2020021109244838600_B11","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2020021109244838600_B12","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020021109244838600_B13","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020021109244838600_B14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020021109244838600_B15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021109244838600_B16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021109244838600_B17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"9976","key":"2020021109244838600_B18","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"2020021109244838600_B19","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2010-10-314260","article-title":"Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I\/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET","volume":"117","author":"Straus","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2020021109244838600_B20","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020021109244838600_B21","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"30","key":"2020021109244838600_B22","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020021109244838600_B23","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2018-99-115173","article-title":"A Phase II study of brentuximab vedotin plus Adriamycin and dacarbazine without radiation in non-bulky limited stage classical Hodgkin lymphoma [abstract]","volume":"132","author":"Abramson","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/7\/606\/1554303\/bloodbld2019001272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/7\/606\/1554303\/bloodbld2019001272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T10:06:49Z","timestamp":1581415609000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/7\/606\/260718\/Brentuximab-vedotin-doxorubicin-vinblastine-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001272","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}